Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?
Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an inter...
Gespeichert in:
| Veröffentlicht in: | Clinical & experimental metastasis 2021-06, Vol.38 (3), p.257-261 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 261 |
|---|---|
| container_issue | 3 |
| container_start_page | 257 |
| container_title | Clinical & experimental metastasis |
| container_volume | 38 |
| creator | Ivanyi, P. Park-Simon, T. Christiansen, H. Gutzmer, R. Vogel, A. Heuser, M. Golpon, H. Hillemanns, P. Haier, J. |
| description | Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient´s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic. |
| doi_str_mv | 10.1007/s10585-021-10083-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2504777261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-59e64f3709bc7b8219a6d1292bffc03ab3b5060a36df7198da9e604bc66edfe53</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EokPhD7BAltiwMb22Ez9YgNCIR6VKgHhsjWM7HVeTeGong_rvcZi2PBasrix_5_hcH4QeU3hOAeRJodCqlgCjpJ4VJ_QOWtFWciKZFHfRCphgBJRWR-hBKRcA0Eip7qMjzmWrAfQKff-Y0xTcFPcBD8GWOYeC-5Txzk4xjFPBP-K0wdbv7eiCx24ZGfs5x_EcT5uAP9tcyDp9I6xqRh-G6F7gT3PCe-tjefUQ3evttoRH1_MYfX375sv6PTn78O50_fqMuEY2E2l1EE3PJejOyU4xqq3wlGnW9b0DbjvetSDAcuF7SbXytgqg6ZwQwfeh5cfo5cF3N3dD8K5mz3ZrdjkONl-ZZKP5-2aMG3Oe9kZqJRlX1eDZtUFOl3MokxlicWG7tWNIczGsXX5PMkEr-vQf9CLNeazrVYrXeC1wqBQ7UC6nUnLob8NQMEuB5lCgqQWaXwWaxfrJn2vcSm4aqwA_AGW3VBDy77f_Y_sTtAWnCQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2537195030</pqid></control><display><type>article</type><title>Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?</title><source>SpringerNature Journals</source><creator>Ivanyi, P. ; Park-Simon, T. ; Christiansen, H. ; Gutzmer, R. ; Vogel, A. ; Heuser, M. ; Golpon, H. ; Hillemanns, P. ; Haier, J.</creator><creatorcontrib>Ivanyi, P. ; Park-Simon, T. ; Christiansen, H. ; Gutzmer, R. ; Vogel, A. ; Heuser, M. ; Golpon, H. ; Hillemanns, P. ; Haier, J.</creatorcontrib><description>Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient´s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic.</description><identifier>ISSN: 0262-0898</identifier><identifier>EISSN: 1573-7276</identifier><identifier>DOI: 10.1007/s10585-021-10083-1</identifier><identifier>PMID: 33759009</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Commentary ; Coronaviruses ; COVID-19 ; Hematology ; Morbidity ; Mortality ; Nosocomial infection ; Oncology ; Pandemics ; Severe acute respiratory syndrome coronavirus 2 ; Surgical Oncology</subject><ispartof>Clinical & experimental metastasis, 2021-06, Vol.38 (3), p.257-261</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-59e64f3709bc7b8219a6d1292bffc03ab3b5060a36df7198da9e604bc66edfe53</citedby><cites>FETCH-LOGICAL-c474t-59e64f3709bc7b8219a6d1292bffc03ab3b5060a36df7198da9e604bc66edfe53</cites><orcidid>0000-0002-2862-7302</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10585-021-10083-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10585-021-10083-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33759009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ivanyi, P.</creatorcontrib><creatorcontrib>Park-Simon, T.</creatorcontrib><creatorcontrib>Christiansen, H.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Vogel, A.</creatorcontrib><creatorcontrib>Heuser, M.</creatorcontrib><creatorcontrib>Golpon, H.</creatorcontrib><creatorcontrib>Hillemanns, P.</creatorcontrib><creatorcontrib>Haier, J.</creatorcontrib><title>Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?</title><title>Clinical & experimental metastasis</title><addtitle>Clin Exp Metastasis</addtitle><addtitle>Clin Exp Metastasis</addtitle><description>Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient´s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Commentary</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Hematology</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Nosocomial infection</subject><subject>Oncology</subject><subject>Pandemics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Surgical Oncology</subject><issn>0262-0898</issn><issn>1573-7276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kUtv1DAUhS0EokPhD7BAltiwMb22Ez9YgNCIR6VKgHhsjWM7HVeTeGong_rvcZi2PBasrix_5_hcH4QeU3hOAeRJodCqlgCjpJ4VJ_QOWtFWciKZFHfRCphgBJRWR-hBKRcA0Eip7qMjzmWrAfQKff-Y0xTcFPcBD8GWOYeC-5Txzk4xjFPBP-K0wdbv7eiCx24ZGfs5x_EcT5uAP9tcyDp9I6xqRh-G6F7gT3PCe-tjefUQ3evttoRH1_MYfX375sv6PTn78O50_fqMuEY2E2l1EE3PJejOyU4xqq3wlGnW9b0DbjvetSDAcuF7SbXytgqg6ZwQwfeh5cfo5cF3N3dD8K5mz3ZrdjkONl-ZZKP5-2aMG3Oe9kZqJRlX1eDZtUFOl3MokxlicWG7tWNIczGsXX5PMkEr-vQf9CLNeazrVYrXeC1wqBQ7UC6nUnLob8NQMEuB5lCgqQWaXwWaxfrJn2vcSm4aqwA_AGW3VBDy77f_Y_sTtAWnCQ</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Ivanyi, P.</creator><creator>Park-Simon, T.</creator><creator>Christiansen, H.</creator><creator>Gutzmer, R.</creator><creator>Vogel, A.</creator><creator>Heuser, M.</creator><creator>Golpon, H.</creator><creator>Hillemanns, P.</creator><creator>Haier, J.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2862-7302</orcidid></search><sort><creationdate>20210601</creationdate><title>Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?</title><author>Ivanyi, P. ; Park-Simon, T. ; Christiansen, H. ; Gutzmer, R. ; Vogel, A. ; Heuser, M. ; Golpon, H. ; Hillemanns, P. ; Haier, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-59e64f3709bc7b8219a6d1292bffc03ab3b5060a36df7198da9e604bc66edfe53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Commentary</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Hematology</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Nosocomial infection</topic><topic>Oncology</topic><topic>Pandemics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ivanyi, P.</creatorcontrib><creatorcontrib>Park-Simon, T.</creatorcontrib><creatorcontrib>Christiansen, H.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Vogel, A.</creatorcontrib><creatorcontrib>Heuser, M.</creatorcontrib><creatorcontrib>Golpon, H.</creatorcontrib><creatorcontrib>Hillemanns, P.</creatorcontrib><creatorcontrib>Haier, J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical & experimental metastasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ivanyi, P.</au><au>Park-Simon, T.</au><au>Christiansen, H.</au><au>Gutzmer, R.</au><au>Vogel, A.</au><au>Heuser, M.</au><au>Golpon, H.</au><au>Hillemanns, P.</au><au>Haier, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?</atitle><jtitle>Clinical & experimental metastasis</jtitle><stitle>Clin Exp Metastasis</stitle><addtitle>Clin Exp Metastasis</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>38</volume><issue>3</issue><spage>257</spage><epage>261</epage><pages>257-261</pages><issn>0262-0898</issn><eissn>1573-7276</eissn><abstract>Cancer patients represent a vulnerable cohort during the Sars-CoV-2 pandemic. Oncological societies have generated a plethora of recommendations, but precise instructions about routine oncological procedures remain scarce. Here, we report on local COVID-19 protection measures established in an interdisciplinary approach at a tertiary care center during the first wave of the pandemia in Germany. Following these measures, no additional morbidity or mortality during oncological procedures was observed, and no nosocomial infections were registered. However, Validation of our measures is outstanding and regional SARS-CoV-2 prevalence was low. However, specific oncological measures might be important to ensure optimal oncological results, especially for advanced cancer stages during this and future pandemia. In the future, communication about these measures might be crucial to a cancer patient´s assigned network to reduce the danger of excess mortality within the second wave of the COVID-19 pandemic.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>33759009</pmid><doi>10.1007/s10585-021-10083-1</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-2862-7302</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0262-0898 |
| ispartof | Clinical & experimental metastasis, 2021-06, Vol.38 (3), p.257-261 |
| issn | 0262-0898 1573-7276 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987238 |
| source | SpringerNature Journals |
| subjects | Biomedical and Life Sciences Biomedicine Cancer Cancer Research Commentary Coronaviruses COVID-19 Hematology Morbidity Mortality Nosocomial infection Oncology Pandemics Severe acute respiratory syndrome coronavirus 2 Surgical Oncology |
| title | Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A40%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20measures%20for%20patients%20with%20advanced%20cancer%20during%20the%20Sars-CoV-2%20pandemic:%20Quo%20vadis?&rft.jtitle=Clinical%20&%20experimental%20metastasis&rft.au=Ivanyi,%20P.&rft.date=2021-06-01&rft.volume=38&rft.issue=3&rft.spage=257&rft.epage=261&rft.pages=257-261&rft.issn=0262-0898&rft.eissn=1573-7276&rft_id=info:doi/10.1007/s10585-021-10083-1&rft_dat=%3Cproquest_pubme%3E2504777261%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2537195030&rft_id=info:pmid/33759009&rfr_iscdi=true |